Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BEATRIZ ELENA ADRADA and ROSALIND PITPITAN CANDELARIA.
BEATRIZ ELENA ADRADA
Connection Strength
4.997
ROSALIND PITPITAN CANDELARIA
  1. MRI for the Staging and Evaluation of Response to Therapy in Breast Cancer. Top Magn Reson Imaging. 2017 Oct; 26(5):211-218.
    View in: PubMed
    Score: 0.635
  2. Imaging and pathological findings in a case of invasive squamous cell carcinoma of the breast. Breast J. 2018 03; 24(2):203-204.
    View in: PubMed
    Score: 0.626
  3. Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated? Am J Surg. 2018 Apr; 215(4):693-698.
    View in: PubMed
    Score: 0.624
  4. Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound Med Biol. 2022 06; 48(6):1010-1018.
    View in: PubMed
    Score: 0.216
  5. Prospective Comparison of Synthesized Mammography with DBT and Full-Field Digital Mammography with DBT Uncovers Recall Disagreements That may Impact Cancer Detection. Acad Radiol. 2022 07; 29(7):1039-1045.
    View in: PubMed
    Score: 0.209
  6. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41.
    View in: PubMed
    Score: 0.206
  7. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887.
    View in: PubMed
    Score: 0.203
  8. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170.
    View in: PubMed
    Score: 0.192
  9. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
    View in: PubMed
    Score: 0.176
  10. Breast cancer neoplastic seeding in the setting of image-guided needle biopsies of the breast. Breast Cancer Res Treat. 2017 Nov; 166(1):29-39.
    View in: PubMed
    Score: 0.157
  11. Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Acad Radiol. 2017 02; 24(2):191-199.
    View in: PubMed
    Score: 0.150
  12. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging. 2024 Jan 31.
    View in: PubMed
    Score: 0.062
  13. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol. 2023; 13:1264259.
    View in: PubMed
    Score: 0.060
  14. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers (Basel). 2023 Oct 02; 15(19).
    View in: PubMed
    Score: 0.060
  15. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.059
  16. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiol Imaging Cancer. 2023 07; 5(4):e230009.
    View in: PubMed
    Score: 0.059
  17. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annu Int Conf IEEE Eng Med Biol Soc. 2023 07; 2023:1-4.
    View in: PubMed
    Score: 0.059
  18. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.059
  19. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
    View in: PubMed
    Score: 0.058
  20. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.058
  21. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel). 2023 Feb 06; 15(4).
    View in: PubMed
    Score: 0.058
  22. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep. 2023 01 20; 13(1):1171.
    View in: PubMed
    Score: 0.057
  23. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer. 2023 Jan 10; 9(1):2.
    View in: PubMed
    Score: 0.057
  24. MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Res. 2022 Sep 16; 82(18):3394-3404.
    View in: PubMed
    Score: 0.056
  25. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell. 2022; 5:876100.
    View in: PubMed
    Score: 0.056
  26. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.055
  27. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2022 12; 56(6):1901-1909.
    View in: PubMed
    Score: 0.055
  28. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.054
  29. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220.
    View in: PubMed
    Score: 0.054
  30. Imaging of Noncalcified Ductal Carcinoma In Situ. J Clin Imaging Sci. 2021; 11:34.
    View in: PubMed
    Score: 0.051
  31. Mimickers of breast malignancy: imaging findings, pathologic concordance and clinical management. Insights Imaging. 2021 Apr 20; 12(1):53.
    View in: PubMed
    Score: 0.051
  32. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2021 07; 54(1):251-260.
    View in: PubMed
    Score: 0.050
  33. MRI features of pseudoangiomatous stromal hyperplasia with histopathological correlation. Breast J. 2021 03; 27(3):242-247.
    View in: PubMed
    Score: 0.050
  34. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
    View in: PubMed
    Score: 0.049
  35. Proliferative fasciitis mimicking sarcoma in the breast. Breast J. 2020 10; 26(10):2072-2074.
    View in: PubMed
    Score: 0.049
  36. High risk breast lesions identified on MRI-guided vacuum-assisted?needle?biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018 Oct; 91(1090):20180300.
    View in: PubMed
    Score: 0.042
  37. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.041
  38. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018 Jul; 25(7):1953-1960.
    View in: PubMed
    Score: 0.041
  39. Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. AJR Am J Roentgenol. 2017 Apr; 208(4):916-922.
    View in: PubMed
    Score: 0.038
  40. Comparison of the accuracy of US-guided biopsy of breast masses performed with 14-gauge, 16-gauge and 18-gauge automated cutting needle biopsy devices, and review of the literature. Eur Radiol. 2017 Jul; 27(7):2928-2933.
    View in: PubMed
    Score: 0.037
  41. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8.
    View in: PubMed
    Score: 0.035
  42. Stereotactic breast biopsy: pitfalls and pearls. Tech Vasc Interv Radiol. 2014 Mar; 17(1):32-9.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.